Real-world incidence and clinical characteristics of intraocular inflammation following intravitreal faricimab therapy: A safety study.

Intraocular inflammation occurred after a median of 4 faricimab injections (IQR: 2, range: 1-9) and a median of 8.5 days (IQR: 20, range: 0-37) after the last injection.

The median disease duration (time from diagnosis to resolution) was 32 days (IQR: 46, range: 6-144).

Eighty per cent of patients who developed intraocular inflammation were females, and females had 2.42-2.66 times higher hazard of developing intraocular inflammation than males.

All panuveitis cases (n = 6) underwent vitrectomy, and one had a positive culture, yielding a 0.003% per-injection incidence of culture-positive endophthalmitis.